RP-6685 is a potent, selective, and orally active inhibitor of DNA polymerase theta (Polθ). RP-6685 exhibits antitumor efficacy in animal models.

RP-6685 is a potent, selective, and orally active inhibitor of DNA polymerase theta (Polθ). RP-6685 exhibits antitumor efficacy in animal models.

RP-6685 is a potent, selective, and orally active inhibitor of DNA polymerase theta (Polθ). RP-6685 exhibits antitumor efficacy in animal models.

SHR2554 is an inhibitor of EZH2. SHR2554 exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels.

SHR2554 is an inhibitor of EZH2. SHR2554 exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels.

SHR2554 is an inhibitor of EZH2. SHR2554 exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels.

DB2313 is a potent inhibitor of the transcription factor PU.1, effectively blocking PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 demonstrated significant anti-leukemic activity by inducing apoptosis in acute myeloid leukemia (AML) cells. It also increases survival rates and reduces tumor burden in vivo.

SHR2554 is an inhibitor of EZH2. SHR2554 exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels.

DB2313 is a potent inhibitor of the transcription factor PU.1, effectively blocking PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 demonstrated significant anti-leukemic activity by inducing apoptosis in acute myeloid leukemia (AML) cells. It also increases survival rates and reduces tumor burden in vivo.

DB2313 is a potent inhibitor of the transcription factor PU.1, effectively blocking PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 demonstrated significant anti-leukemic activity by inducing apoptosis in acute myeloid leukemia (AML) cells. It also increases survival rates and reduces tumor burden in vivo.